KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Accumulated Expenses (2016 - 2020)

Regeneron Pharmaceuticals (REGN) has 10 years of Other Accumulated Expenses data on record, last reported at $122.4 million in Q4 2020.

  • For Q4 2020, Other Accumulated Expenses rose 44.0% year-over-year to $122.4 million; the TTM value through Dec 2020 reached $122.4 million, up 44.0%, while the annual FY2020 figure was $122.4 million, 44.0% up from the prior year.
  • Other Accumulated Expenses reached $122.4 million in Q4 2020 per REGN's latest filing, up from $103.8 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $122.4 million in Q4 2020 and bottomed at $267000.0 in Q4 2017.
  • Average Other Accumulated Expenses over 4 years is $30.5 million, with a median of $3.6 million recorded in 2016.
  • Peak YoY movement for Other Accumulated Expenses: surged 518.22% in 2016, then crashed 93.51% in 2017.
  • A 4-year view of Other Accumulated Expenses shows it stood at $1.2 million in 2016, then crashed by 77.33% to $267000.0 in 2017, then surged by 31735.21% to $85.0 million in 2019, then surged by 44.0% to $122.4 million in 2020.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $122.4 million in Q4 2020, $103.8 million in Q2 2020, and $85.0 million in Q4 2019.